- Trials with a EudraCT protocol (17)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (26)
17 result(s) found for: Antimicrobial agent.
Displaying page 1 of 1.
EudraCT Number: 2018-003321-29 | Sponsor Protocol Number: 17-169 | Start Date*: Information not available in EudraCT |
Sponsor Name:RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical Faculty | ||
Full Title: Clinical relevance of the antimicrobial resistance testing in the treatment of chronic wounds with antiseptics | ||
Medical condition: Decubitus, acute or chronic wounds (open wounds existing ≥ 14 days) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-001855-37 | Sponsor Protocol Number: OCT02-2006 | Start Date*: 2007-05-14 | |||||||||||
Sponsor Name:Schülke & Mayr GmbH | |||||||||||||
Full Title: Effect of an octenidine-based topical antimicrobial agent (Octenisept) on wound healing of chronic venous leg ulcers: a prospective, twelve-week comparison versus local treatment with Ringer soluti... | |||||||||||||
Medical condition: Chronic venous leg ulcers In Germany, approximately three million people suffer from chronic leg ulcers of various origins. These ulcers are often very painful and extremely cost-intensive disease... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) FR (Completed) HU (Prematurely Ended) GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004037-10 | Sponsor Protocol Number: CE01-119 | Start Date*: 2014-10-10 |
Sponsor Name:Cempra Pharmaceuticals, Inc. | ||
Full Title: A phase 1, open-label, multi-centre study to determine the PK and safety of a 5-day oral dosing of solithromycin as add-on therapy to antimicrobial agent administered to adolescent with suspected o... | ||
Medical condition: suspected or confirmed bacterial infection | ||
Disease: | ||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2008-006153-41 | Sponsor Protocol Number: J&P004/2008 | Start Date*: 2009-03-30 |
Sponsor Name:Medical university Graz, Department of Plastic Surgery | ||
Full Title: Target site pharmacokinetics of linezolid after repetitive doses in diabetic patients with bacterial foot infection | ||
Medical condition: The study population will consist of a representative group of adult male or female patients with documented diabetes and bacterial soft tissue infection of the foot complicated by osteomyelitis. P... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2021-001396-16 | Sponsor Protocol Number: OP0595-6 | Start Date*: 2023-03-29 | |||||||||||||||||||||||||||||||
Sponsor Name:Meiji Seika Pharma Co., Ltd. | |||||||||||||||||||||||||||||||||
Full Title: A Phase 3, Multi-Center, Randomized, Single-Blind Study to Assess the Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy in Adults With Complicated Ur... | |||||||||||||||||||||||||||||||||
Medical condition: Complicated urinary tract infection (cUTI), acute uncomplicated pyelonephritis (AP), hospital acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and complicated ... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: FR (Trial now transitioned) SK (Trial now transitioned) GR (Trial now transitioned) LV (Trial now transitioned) ES (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004041-26 | Sponsor Protocol Number: CE01-120 | Start Date*: 2014-10-10 |
Sponsor Name:Cempra Pharmaceuticals , Inc | ||
Full Title: A Phase I, open-label, multi-centre study to evaluate the PK and safety of solithromycin as add-on therapy to antimicrobial agent administered to paediatric subjects with a suspected or confirmed b... | ||
Medical condition: suspected or confirm bacterial infection | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2019-004947-65 | Sponsor Protocol Number: IMPACT-TDM | Start Date*: 2021-05-17 | |||||||||||||||||||||
Sponsor Name:Santiago Grau Cerrato | |||||||||||||||||||||||
Full Title: IMPACT ON THE CLINICAL OUTCOMES AND COST-EFFECTIVENESS OF THE ANTIMICROBIAL THERAPEUTIC MONITORING PROGRAM IN CRITICAL PATIENTS | |||||||||||||||||||||||
Medical condition: - Respiratory infections - Urogenital infections - Abdominal infections | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005112-37 | Sponsor Protocol Number: J&P 01/2007 draft4 | Start Date*: 2008-08-21 | |||||||||||
Sponsor Name:Medizinische Universität Wien, Abteilung für Interne Medizin I | |||||||||||||
Full Title: An randomized, controlled, investigator-blinded, prospective, mono-centre study to evaluate the efficacy of fosfomycin versus meropenem in patients with complicated urinary tract infections | |||||||||||||
Medical condition: This study will primarily address the question of the efficacy of intravenous fosfomycin 4 g b.i.d. in the therapy of patients presenting with complicated urinary tract infection. These data will b... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002677-57 | Sponsor Protocol Number: PREVAN | Start Date*: 2021-11-04 | |||||||||||
Sponsor Name:Dra. Julia Origüen Sabater | |||||||||||||
Full Title: A phase III, multicenter, randomized, double-blind clinical trial to evaluate the efficacy and safety of oral vancomycin versus placebo in preventing relapse of Clostridioides difficile infection i... | |||||||||||||
Medical condition: Patients at high risk of recurrence due to CDI who require hospitalization and who increase morbidity and mortality from new CDI. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004880-29 | Sponsor Protocol Number: HUB-INF-RADICAP | Start Date*: 2019-10-02 | |||||||||||
Sponsor Name:Dr. Jordi Carratalà Fernández (Servicio de Enfermedades Infecciosas) del Hospital Universitario de Bellvitge | |||||||||||||
Full Title: Phase IV randomized, controlled, open and multicentre clinical trial with two parallel groups, to assess the impact of integral molecular tests in the antimicrobial use in community-acquired pneumo... | |||||||||||||
Medical condition: Community-acquired pneumonia (CAP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022128-63 | Sponsor Protocol Number: LX211-11 | Start Date*: 2011-03-16 |
Sponsor Name:Lux Biosciences, Inc. | ||
Full Title: A Multi-center, Double-Masked, Parallel Group, Placebo-Controlled Study to Assess the Efficacy and Safety of Voclosporin as Therapy in Subjects with Active Non-Infectious Uveitis Involving the Inte... | ||
Medical condition: Non-Infectious Intermediate, Posterior or Pan-uveitis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) IT (Completed) GB (Completed) NL (Ongoing) CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-000546-30 | Sponsor Protocol Number: Rempex-506 | Start Date*: 2015-04-21 | |||||||||||||||||||||||||||||||
Sponsor Name:Rempex Pharmaceuticals, Inc. | |||||||||||||||||||||||||||||||||
Full Title: A PHASE 3, MULTI-CENTER, RANDOMIZED, OPEN-LABEL STUDY OF CARBAVANCE (MEROPENEM/RPX7009) VERSUS BEST AVAILABLE THERAPY IN SUBJECTS WITH SELECTED SERIOUS INFECTIONS DUE TO CARBAPENEM RESISTANT ENTERO... | |||||||||||||||||||||||||||||||||
Medical condition: serious infections, specifically complicated urinary tract infection (cUTI) or acute pyelonephritis (AP), complicated intra-abdominal infections (cIAI), hospital acquired bacterial pneumonia (HABP... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) IT (Completed) ES (Completed) GR (Completed) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005169-63 | Sponsor Protocol Number: NAB-BC-3781-3101 | Start Date*: 2016-01-12 | |||||||||||
Sponsor Name:Nabriva Therapeutics AG | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community... | |||||||||||||
Medical condition: Community-Acquired Bacterial Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) HU (Completed) LV (Completed) PL (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019984-12 | Sponsor Protocol Number: AMNCH-TCD-CHG-1-2010 | Start Date*: 2010-07-21 |
Sponsor Name:Adelaide & Meath Hospital, incorporating The National Children's Hospital | ||
Full Title: A multicentre randomised trial comparing the effects of 2% chlorhexidine gluconate in 70% isopropyl alcohol as a skin, exit site and catheter hub cleansing agent versus other forms of chlorhexidine... | ||
Medical condition: Prevention of central venous catheter-related infections in haemodialysis patients. This trial will evaluate the effectiveness of 2% chlorhexidine gluconate in 70%isopropyl alcohol as a skin, exit... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-003741-17 | Sponsor Protocol Number: PMX63-203 | Start Date*: 2012-01-17 | |||||||||||
Sponsor Name:PolyMedix Inc. | |||||||||||||
Full Title: Randomized, Dose Ranging, Active Controlled Efficacy and Safety Evaluation of PMX-30063 As Initial Treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Staphylococcus... | |||||||||||||
Medical condition: Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Caused by Staphylococcus aureus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002636-31 | Sponsor Protocol Number: APHP211034 | Start Date*: 2022-09-15 |
Sponsor Name:Assistance Publique Hôpitaux de Paris/DRCI | ||
Full Title: Piperacillin-tazobactam and temocillin as carbapenem-alternatives for the treatment of severe infections due to extended-spectrum beta-lactamase–producing Gram-negative Enterobacteriaceae in the in... | ||
Medical condition: severe infections due to extended-spectrum beta-lactamase–producing Gram-negative Enterobacteriaceae | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004782-92 | Sponsor Protocol Number: NAB-BC-3781-3102 | Start Date*: 2016-07-26 | |||||||||||
Sponsor Name:Nabriva Therapeutics AG | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC-3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia | |||||||||||||
Medical condition: Community-acquired bacterial pneumonia (CABP) is a commonly occurring serious infection that requires systemic antibiotic therapy and is associated with substantial morbidity, mortality, and consid... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) HU (Completed) ES (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
